Skip to main content
Premium Trial:

Request an Annual Quote

Millipore Exploring Alternatives Following News of Acquisition Bid

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Millipore said late last night that its board of directors is evaluating "strategic alternatives to enhance shareholder value," including a potential merger or sale of the company.

Millipore's statement comes two days after Bloomberg reported that Thermo Fisher Scientific had made a $6 billion bid for the firm. Millipore did not respond to a request from GenomeWeb Daily News for comment earlier this week, while Thermo Fisher officials said they would not comment on rumors.

Millipore confirmed that it has hired Goldman Sachs as its financial advisor and Cravath, Swaine & Moore as its legal advisor to assist the board in its evaluation.

Millipore also said that it has not set a timetable for completing the evaluation and cannot assure that it will lead to any transaction.

In early Wednesday trade on the New York Stock Exchange, shares of Millipore were up 3 percent at $91.50. Its shares are up 28 percent for the week.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.